Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Gastroenterology - United Kingdom
doi 10.1053/j.gastro.2017.07.032
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2017English

Letter: Therapeutic Drug Monitoring and Inflammatory Bowel Disease-A Call for an Urgent Standardization of the Results

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Novel Therapeutic Targets in Inflammatory Bowel Disease

Prescriber
Pharmacology
2019English

Recommended Drug Therapies for Inflammatory Bowel Disease

Prescriber
Pharmacology
2018English

Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease

Clinical Endoscopy
MedicineNuclear MedicineRadiologyImagingGastroenterology
2017English

Editorial: Infliximab De-Escalation in Inflammatory Bowel Disease Using a Therapeutic Drug Monitoring Strategy - Early Promise but More Data Needed. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Review Article: Consensus Statements on Therapeutic Drug Monitoring of Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Making Therapeutic Decisions in Inflammatory Bowel Disease: The Role of Patients

Current Opinion in Gastroenterology
Gastroenterology
2009English

Inflammatory Bowel Disease

Annual Review of Immunology
AllergyImmunology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy